Sanofi successfully prices EUR 8 billion of bond issues
15 Março 2018 - 03:00AM
|
Press Release
Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) |
Sanofi successfully prices EUR 8 billion of bond
issues
Paris, France - March 15, 2018 - Sanofi has
successfully priced its offering of EUR 8 billion of notes (the
"Notes") across 6 tranches:
- €1.0 billion floating rate notes, due March 2020,
bearing interest at a quarterly rate of 3-month EURIBOR + 15
bp
- €0.5 billion fixed rate notes, due March 2020,
bearing interest at an annual rate of 0.0%
- €1.75 billion fixed rate notes, due March 2023,
bearing interest at an annual rate of 0.5%
- €1.5 billion fixed rate notes, due March 2026,
bearing interest at an annual rate of 1.0%
- €2.0 billion fixed rate notes, due March 2030,
bearing interest at an annual rate of 1.375%
- €1.25 billion fixed rate notes, due March 2038,
bearing interest at an annual rate of 1.875%
The issues are made under the company's Euro Medium Term Note
Programme.
The transaction enables the company to lower its average cost of
debt and extend the average maturity of its debt.
Sanofi intends to use the net proceeds of the offering for general
corporate purposes, including the financing of the acquisitions of
Bioverativ and Ablynx.
BNP Paribas, Société Générale CIB and UniCredit Bank acted as
Global Coordinators and Bookrunners, alongside Crédit Agricole CIB,
Citi, HSBC, ING, J.P. Morgan, RBC Capital Markets and Santander
which acted as Bookrunners for the offering.
|
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
|
Media Relations Contact Laurence
Bollack
Tel.: +33 (0)1 53 77 46 46
mr@sanofi.com
|
Investor Relations Contact George
Grofik
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com
|
DISCLAIMER This
communication shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
The Notes have not been and will not be registered
under the Securities Act and may not be offered or sold within the
United States or to, or for the account or benefit of, U.S. persons
except in certain transactions exempt from the registration
requirements of the Securities Act.
PROHIBITION OF SALES TO EEA RETAIL INVESTORS - The
Notes are not intended to be offered, sold or otherwise made
available to and should not be offered, sold or otherwise made
available to any Retail Investor in the European Economic Area
("EEA"). For these purposes, a "Retail Investor" means a person who
is one (or more) of: (i) a retail client as defined in point (11)
of Article 4(1) of Directive 2014/65/EU ("MiFID II"); or (ii) a
customer within the meaning of Directive 2002/92/EC ("IMD"), where
that customer would not qualify as a professional client as defined
in point (10) of Article 4(1) of MiFID II. Consequently no key
information document required by Regulation (EU) No 1286/2014 (the
"PRIIPs Regulation") for offering or selling the Notes or otherwise
making them available to retail investors in the EEA has been or
will be prepared and therefore offering or selling the Notes or
otherwise making them available to any retail investor in the EEA
may be unlawful under the PRIIPS Regulation.
This communication is only being distributed to and is only
directed at (i) persons who are outside the United Kingdom or (ii)
investment professionals falling within Article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order
2005 (the "Order") or (iii) high net worth companies, and other
persons to whom it may lawfully be communicated, falling within
Article 49(2)(a) to (d) of the Order or (iv) persons to whom an
invitation or inducement to engage in investment activity (within
the meaning of section 21 of the Financial Services and Markets Act
2000) may otherwise lawfully be communicated or cause to be
communicated (all such persons together being referred to as
"relevant persons"). The Notes are only available to, and any
invitation, offer or agreement to subscribe, purchase or otherwise
acquire such Notes will be engaged in only with, relevant persons.
Any person who is not a relevant person should not act or rely on
this document or any of its contents.
No Notes have been offered or sold nor will be offered or sold,
directly or indirectly, to the public in France; the Base
Prospectus or any other offering material relating to the Notes
have not been distributed or caused to be distributed and will not
be distributed or caused to be distributed to the public in France;
such offers, sales and distributions have been and shall only be
made in France to persons licensed to provide the investment
service of portfolio management for the account of third parties or
to qualified investors (investisseurs qualifiés) other than
individuals, investing for their own account, all as defined in
Articles L. 411-1, L. 411-2 and D. 411-1 of the French Code
monétaire et financier.
Forward-Looking
Statements Any statements
made in this communication that are not statements of historical
fact, including statements about Sanofi's beliefs and expectations
are forward-looking statements and should be evaluated as such.
Forward-looking statements include statements that may relate to
Sanofi's plans, objectives, strategies, goals, future events,
future revenues or performance, and other information that is not
historical information. Sanofi does not undertake, and specifically
disclaims, any obligation or responsibility to update or amend any
of the information above except as otherwise required by
law.
Additional Information: This communication is neither an
offer to purchase nor a solicitation of any offer to sell any
securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. |
Press release (PDF).
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Sanofi via Globenewswire
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024